Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs from Ebola Virus Disease

Michelle Meyer, Eric Huang, Olga Yuzhakov, Palaniappan Ramanathan, Giuseppe Ciaramella, Alexander Bukreyev

    Research output: Contribution to journalArticle

    9 Citations (Scopus)

    Abstract

    Most current Ebola virus (EBOV) vaccine candidates are based on viral vectors, some of which cause side effects or require complex manufacturing. Modified mRNA vaccines are easily produced, safe, and are highly immunogenic. We developed 2 mRNA vaccines based on the EBOV envelope glycoprotein, which differed by the nature of signal peptide for improved glycoprotein post-translational translocation. The mRNAs were formulated with lipid nanoparticles to facilitate delivery. Vaccination of Guinea pigs induced EBOV-specific IgG and neutralizing antibody responses and 100% survival after EBOV infection. The efficacy of our mRNA vaccine combined with preclinical safety data supports testing in clinical studies.

    Original languageEnglish (US)
    Pages (from-to)451-455
    Number of pages5
    JournalJournal of Infectious Diseases
    Volume217
    Issue number3
    DOIs
    StatePublished - Jan 17 2018

    Fingerprint

    Ebola Hemorrhagic Fever
    Guinea Pigs
    Vaccines
    Messenger RNA
    Ebola Vaccines
    Ebolavirus
    Combined Vaccines
    Protein Sorting Signals
    Neutralizing Antibodies
    Nanoparticles
    Antibody Formation
    Glycoproteins
    Vaccination
    Immunoglobulin G
    Lipids
    Safety

    Keywords

    • antibody response
    • Ebola virus
    • immunization
    • RNA
    • vaccine

    ASJC Scopus subject areas

    • Immunology and Allergy
    • Infectious Diseases

    Cite this

    Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs from Ebola Virus Disease. / Meyer, Michelle; Huang, Eric; Yuzhakov, Olga; Ramanathan, Palaniappan; Ciaramella, Giuseppe; Bukreyev, Alexander.

    In: Journal of Infectious Diseases, Vol. 217, No. 3, 17.01.2018, p. 451-455.

    Research output: Contribution to journalArticle

    Meyer, Michelle ; Huang, Eric ; Yuzhakov, Olga ; Ramanathan, Palaniappan ; Ciaramella, Giuseppe ; Bukreyev, Alexander. / Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs from Ebola Virus Disease. In: Journal of Infectious Diseases. 2018 ; Vol. 217, No. 3. pp. 451-455.
    @article{5625d1f083cd4a03bee7fb52139a9c85,
    title = "Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs from Ebola Virus Disease",
    abstract = "Most current Ebola virus (EBOV) vaccine candidates are based on viral vectors, some of which cause side effects or require complex manufacturing. Modified mRNA vaccines are easily produced, safe, and are highly immunogenic. We developed 2 mRNA vaccines based on the EBOV envelope glycoprotein, which differed by the nature of signal peptide for improved glycoprotein post-translational translocation. The mRNAs were formulated with lipid nanoparticles to facilitate delivery. Vaccination of Guinea pigs induced EBOV-specific IgG and neutralizing antibody responses and 100{\%} survival after EBOV infection. The efficacy of our mRNA vaccine combined with preclinical safety data supports testing in clinical studies.",
    keywords = "antibody response, Ebola virus, immunization, RNA, vaccine",
    author = "Michelle Meyer and Eric Huang and Olga Yuzhakov and Palaniappan Ramanathan and Giuseppe Ciaramella and Alexander Bukreyev",
    year = "2018",
    month = "1",
    day = "17",
    doi = "10.1093/infdis/jix592",
    language = "English (US)",
    volume = "217",
    pages = "451--455",
    journal = "Journal of Infectious Diseases",
    issn = "0022-1899",
    publisher = "Oxford University Press",
    number = "3",

    }

    TY - JOUR

    T1 - Modified mRNA-Based Vaccines Elicit Robust Immune Responses and Protect Guinea Pigs from Ebola Virus Disease

    AU - Meyer, Michelle

    AU - Huang, Eric

    AU - Yuzhakov, Olga

    AU - Ramanathan, Palaniappan

    AU - Ciaramella, Giuseppe

    AU - Bukreyev, Alexander

    PY - 2018/1/17

    Y1 - 2018/1/17

    N2 - Most current Ebola virus (EBOV) vaccine candidates are based on viral vectors, some of which cause side effects or require complex manufacturing. Modified mRNA vaccines are easily produced, safe, and are highly immunogenic. We developed 2 mRNA vaccines based on the EBOV envelope glycoprotein, which differed by the nature of signal peptide for improved glycoprotein post-translational translocation. The mRNAs were formulated with lipid nanoparticles to facilitate delivery. Vaccination of Guinea pigs induced EBOV-specific IgG and neutralizing antibody responses and 100% survival after EBOV infection. The efficacy of our mRNA vaccine combined with preclinical safety data supports testing in clinical studies.

    AB - Most current Ebola virus (EBOV) vaccine candidates are based on viral vectors, some of which cause side effects or require complex manufacturing. Modified mRNA vaccines are easily produced, safe, and are highly immunogenic. We developed 2 mRNA vaccines based on the EBOV envelope glycoprotein, which differed by the nature of signal peptide for improved glycoprotein post-translational translocation. The mRNAs were formulated with lipid nanoparticles to facilitate delivery. Vaccination of Guinea pigs induced EBOV-specific IgG and neutralizing antibody responses and 100% survival after EBOV infection. The efficacy of our mRNA vaccine combined with preclinical safety data supports testing in clinical studies.

    KW - antibody response

    KW - Ebola virus

    KW - immunization

    KW - RNA

    KW - vaccine

    UR - http://www.scopus.com/inward/record.url?scp=85041227397&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85041227397&partnerID=8YFLogxK

    U2 - 10.1093/infdis/jix592

    DO - 10.1093/infdis/jix592

    M3 - Article

    VL - 217

    SP - 451

    EP - 455

    JO - Journal of Infectious Diseases

    JF - Journal of Infectious Diseases

    SN - 0022-1899

    IS - 3

    ER -